Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 January 2022 | Story Leonie Bolleurs | Photo Supplied
Director and co-producer Mpendulo Myeni believes when it comes to making it in the film industry, one should use all the resources and opportunities you have at your disposal.

A single, unemployed mother; institutional corruption, blackmail, and the powerful players behind it. These are all ingredients for a 29-minute short film, Leshano, currently available on Showmax. 

Mpendulo Myeni, director and co-producer of the production that was filmed between Bloemfontein and Bothshabelo last year, says he was initially attracted to the script by writer and executive producer, Anton Fisher (a former Director of Strategic Communications at the UFS). “Hearing his creative ideas, I fell deeper into the storyline, wanting to explore the story and tell it with my own voice.”

Besides Myeni’s involvement with Leshano (The Lie), which was filmed in Sesotho with English subtitles, a number of other Free State artists contributed to the film. Napo Masheane, who grew up in Qwaqwa, was cast in the lead role. He is supported by Maria de Koker, Vincent Tsoametsi, Seipati Mpotoane, Pesa Pheko, Ntsiki Ndzume, and Shayne Nketsi. 

Aspiring filmmakers in the province also had the opportunity to be part of this success story, whether as make-up artists, wardrobe assistants, or location scouts. 

Myeni says Bloemfontein artists and spectators are excited to see that a film shot locally has been accepted by the streaming service, Showmax. “The story has been welcomed and has had an overwhelming response on social media by the Free State audiences. Dignitaries in the Free State Provincial Department of Sports, Arts, Culture and Recreation also positively commented on social media.”

“The Free State audience has embraced our creative expression. Many have requested for the story to be turned into a series,” he says.

Creative at heart

Myeni, a creative at heart, studied Drama and Theatre Arts, as well as Film and Visual Media up to honours level at the UFS. He also had the opportunity to study as exchange student at the University of Groningen in their film master's programme.

The international experience ignited his passion for filming and got him fired up and ready to create. He was involved in the production of several films. “I co-wrote and directed Eyelash (2020), which won a jury award, iamAFRICA, at the Pan African Film Festival in Los Angeles. This led me to create the critically acclaimed lockdown film, called Let Me Out. This film was praised by notable film critic Robyn Sassen as ‘a coronavirus gem’, like Vincent Mantsoe’s dance piece, Cut … to materialise on the cultural sphere, and it deserves as much attention as it can garner.” Another recent creation from Myeni is Amanzi, a short film yet to be released. “I also directed The Lie and collaborated with amazing creatives during the venture,” he elaborates. 

The complete Eyelash experience, winning the iamAFRICA award at the Pan African Film Festival in Los Angeles, might have been one of those life-changing moments for Myeni. He confirms: “Going to America was definitely an out-of-this-world experience, especially being such a big accomplishment – winning an internationally recognised film award from a distinguished film festival. I also got to meet and talk to the director of YouTube originals, as well as other filmmaking creatives.”

Firm foundations

Besides being an UFS alumnus and award-winning filmmaker, Myeni, who on a previous occasion received the Richard Miles award in the Faculty of the Humanities, is now working as an assistant officer in the Department of Architecture at the UFS. “I largely work with research and the creative outputs of postgraduate students. Furthermore, I manage the research hub and library and I also run the visual media aspect within the department.”

In addition, Myeni is also completing his master’s degree in Film and Visual Media at the university. “The academia and higher learning are very important to me; you can say that I am motivated by the academic avenues and learning opportunities that my position affords me,” he says. 

He believes that any lived experience will give insight into your character and abilities. “This experience in the film industry will carry me through to give more of myself in my current position, both academically and creatively.”

“I will never stop creating; my future holds more films, with me involved in producing and directing them.” In five years’ time, I see myself having been the creator of at least three other short films, and one feature film,” concludes Myeni.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept